Clinical Evaluation of Tumour Marker Combinations in the Differential Diagnosis of Benign and Malignant Liver Disease
| Autor: | C. B. Wood, O. Nilsson, N. A. Habib, M. E. Lucarotti, C. Johanssen, N. D. Rothnie, Robin C. N. Williamson, S. B. Kelly, L. Lindholm, M. J. Hershman |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Pathology
medicine.medical_specialty endocrine system diseases medicine.drug_class Biliary Tract Diseases lcsh:Surgery Monoclonal antibody Diagnosis Differential Liver disease Carcinoembryonic antigen medicine Carcinoma Humans Antigens Tumor-Associated Carbohydrate lcsh:RC799-869 Immunoradiometric assay Hepatology biology business.industry Liver Diseases Liver Neoplasms Hepatobiliary disease lcsh:RD1-811 medicine.disease digestive system diseases Carcinoembryonic Antigen Biliary Tract Neoplasms biology.protein Immunoradiometric Assay lcsh:Diseases of the digestive system. Gastroenterology Surgery Antibody Differential diagnosis business Research Article |
| Zdroj: | HPB Surgery, Vol 5, Iss 1, Pp 23-28 (1991) HPB Surgery |
| ISSN: | 0894-8569 |
| DOI: | 10.1155/1991/23874 |
| Popis: | CEA, CA19-9 and CA50 are tumour associated antigens defined by monoclonal antibodies which have been raised against adenocarcinoma cell lines. The aim of this study was to determine whether their combined use could improve diagnostic accuracy in patients with primary and secondary liver tumours. An immunoradiometric assay was used for the detection of CEA and CA19-9 and the Delfia system for CA50. Serum was collected from 65 normal subjects, 40 with hepatobiliary carcinoma (26 primary, 14 secondary) and 17 with benign hepatobiliary disease. The cut-off levels were calculated as the mean of the control group plus 2 standard deviations. All three antibodies contributed to improving the correct classification of secondary liver tumours (multivariant discriminant analysis p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text